Curtis Studey, MD
Radiation Oncology · Weatherford, TXNPI 1821090002
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $392, more than ten times the $34 reported in 2022.
Across 54 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$108
- Novartis$60
- AstraZeneca$55
- Bayer$55
- AVEO Pharmaceuticals, Inc.$53
- Immunocore Limited$53
- plus $748 from 27 others
What the payments were for
- Food & beverage$1,132100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $108 |
| Novartis | 3 | $60 |
| AstraZeneca | 3 | $55 |
| Bayer | 3 | $55 |
| AVEO Pharmaceuticals, Inc. | 2 | $53 |
| Immunocore Limited | 2 | $53 |
| Incyte Corporation | 2 | $53 |
| Deciphera Pharmaceuticals Inc. | 2 | $53 |
| Servier Pharmaceuticals LLC | 2 | $49 |
| Astellas Pharma US Inc | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Spectrum Pharmaceuticals Inc. | 2 | $43 |
| Immunogen, Inc. | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Seagen Inc. | 2 | $31 |
| Sanofi | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Genmab U.S., Inc. | 1 | $24 |
| Geron Corporation | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| AbbVie | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Caris MPI, Inc. | 1 | $14 |
How this compares
$1,132 in reported general payments places this provider in the 60th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Weatherford
- Aaron LaineWeatherford$5K
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.